Hot Investor Mandate: VC Firm Invests Up to $10M, Focused Exclusively in New Investments in Oncology Therapies Across the Globe

17 Dec

A global investor exclusively focused on the development of oncology therapies is headquartered in Western Europe; the firm makes selective investments in early-stage drug development companies targeting cancer therapies that can bring solid proof of concept to the table. Typically, the firm invests in incorporated companies from late seed stage to early series B. The investment size will vary, and it can range from 3 to 10 million dollars with the possibility of investing lower amounts for seed stage companies. The firm may make 3-4 investments in the next year, depending on the opportunity. The firm has no geographic restriction and is actively seeking new investment opportunities across the globe.

In the life sciences, the firm is currently seeking new investments targeting the development of oncology therapies, and is open to all types of therapeutic modalities and all indications within the oncology space, including platform technology that has a lead oncology therapeutic product. The firm will typically not invest in medical devices or diagnostics, unless as companion to a therapeutic solution. Project will be evaluated on solid preclinical proof-of-concept (late preclinical stage/pre-IND or early clinical), and will often fund the companies at least up to human proof-of-concept (clinical Phase Ib – Phase IIa).

Representative portfolio companies include: ARCUS Biosciences (Hayward, CA), developing small-molecule and antibody compounds targeting tumor related immune suppression, enhanced APC function and immune cell efficacy; Tusk Therapeutics (Stevenage, UK), developing novel immune modulating antibody therapeutics to harness the immune system against cancer; Octimet (Beerse, Belgium), a spin-out company from Janssen Pharmaceuticals developing a new generation of highly selective MET kinase activity inhibitors with augmented therapeutic index; Convert Pharmaceuticals (Liege, Belgium), developing hypoxia activated pro-cytotoxic small molecules; and Cristal Therapeutics (Maastricht, The Netherlands), developing a versatile nanoparticle platform which allows payload delivery in the tumor micro-environment.

The firm only invests in private companies with experienced management teams and breakthrough potential. The firm most often takes the responsibility to be lead investor, alone or in syndicate as the opportunity demands, and wants to be actively involved in the successful development and growth of the portfolio companies. To this end, the firm has several experts in oncology, intellectual property and drug development on the investment team and available to the portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: